Team

Inna Zhuranskaya CDir brings over 20 years of experience across global private equity, venture capital and investment institutions, including GIC, Singapore’s sovereign wealth fund, Bank of America and Deutsche Bank. Throughout her career, she has originated and closed transactions across life sciences and real estate and raised more than $2B from institutional and private investors. She has served as CEO of Allrise Capital, with $2 billion in assets under management, and CIO of Yoo Group, overseeing a $4 billion portfolio. She is also an exited co-founder of a hospitality business and an active angel investor, including in Altovita, a technology-enabled proptech and hospitality platform. Inna has served on the board of Alkor Bio Group/Astra Biotech, where she oversaw a joint venture with Newcastle University focused on mesenchymal stem cell therapies and led the company’s M&A activity. She has also served as an academy governor within the Future Academies Trust, established by Lord John Nash, a former chair of the British Venture Capital Association and Conservative Parliamentary Under Secretary of State for Schools. A Chartered Director, Inna is a Chartered Member of the Chartered Institute for Securities & Investment and holds an LLM from the University of Cambridge and an MSc in Real Estate Economics and Finance from the London School of Economics. She has been invited twice to the House of Lords in recognition of her contributions to Future Academies and UK healthcare, and was recognised as a leading woman in private equity at the Women in Private Markets Summit.

Dr. Ludovico Pipito is a computational chemist and ML engineer developing cutting-edge solutions for drug discovery. At Alosenta he bridges biochemistry and AI to reduce chemotherapy toxicity, while maintaining his academic role as Research Fellow at Coventry University. He pioneered themultiple-walker supervised molecular dynamics(mwSuMD), an unbias method to accelerate 100x the sampling of rare biochemical events, and developed scalable QM-refined HTVS pipelines for drug discovery and FEP evaluation. He also applies computational chemistry and ML to unveil the biological mechanism of depalmitoylating enzymes.

He actively collaborates with AstraZeneca on antigen-antibody epitope modelling (EpiFinder) and LLM-based molecule generation. He is specialised in drug discovery for cancer, while authoring numerous publications on SARS-CoV-2 therapeutics, HIV inhibitors, and innovative computational method development, building scalable pipelines that combine QM, FEP, and neural networks to industry standards.

Mr. Serge Platonow is an accomplished executive with extensive experience in PE and investment management. He serves as Non-Executive Chairman at Alosenta. Mr. Platonow is also a Principal at the Hayrish Group, a investment firm specialising in real estate and PE. Prior to this, he held senior leadership positions at Chelsfield, a global investment and development firm, where he served as Managing Director for Europe, overseeing major capital projects.

Mr. Platonow has also worked at Colony Capital (now DigitalBridge), a leading investment firm with over £50B in AUM where he was CIO of its real estate and infrastructure arm, Colyzeo Investment Management. He has served on the boards of prestigious organisations, including Paris Saint-Germain Football Club and Lucia SA. Mr. Platonow holds an MBA from INSEAD, an MSc from the MIT. He is the son of the late Nicolas Platonow, a prominent toxicologist and advisor to the Canadian government.

They are split across wet lab, dry lab (computational) and business functions, and bring their experiences from institutions including UCL Cancer Institute, AstraZeneca, P&G, Benevolent AI, Huntsman Advanced Materials and the National Research and Development Institute for Isotope and Molecular Technologies.

Professor Meirovitz is Chairman of Oncology at Soroka University Medical Centre and Professor at Ben-Gurion University. A specialist in radiation oncology and internal medicine, he focuses on head and neck, urological, gynaecological, and lung cancers. He leads advanced radiotherapy techniques like IMRT, SBRT, and brachytherapy.

His research centres on molecular and radiation biology, especially the tumour microenvironment. With over 20 years of experience, he is passionate about innovation and translational cancer care.

Fellow in Biometrology, Head of Engineering Biology, Professor of Biophysics, National Physical Laboratory. Visiting Professor, King’s College London.

Consultant Obstetrician & Gynaecologist, The Portland Hospital. Honorary Senior Lecturer, Imperial College.

Senior Director AI for DeepTech & Corporate Venture Office, Hitachi.

Mr. Choy-Soon Chua is the founder and Managing Director of Cedar Investment Management in Singapore, with over 25 years of global real estate investment experience. He began his career in 1995 with GIC Real Estate, the sovereign wealth fund, in San Francisco, and went on to cover the European markets from Frankfurt and London.

As Chief Investment Officer of SEB Asset Management in Frankfurt, he was responsible for global real estate investment of over US$12 billion and led the group’s investments into Asia from 2006. He holds a Dipl. Ing. from the Hamburg University of Applied Sciences and speaks German and Mandarin.

Vytenis Sakalas is the CEO of Moterra, a secure enterprise AI platform, with over 15 years of experience in cloud, DevOps, and IT governance. He focuses on making AI practical for businesses by developing private, secure, and cost-effective AI solutions that integrate with existing systems, particularly for SMBs and regulated industries.

Mr. John Finnemore is a Partner in the CMS Corporate Team (CMS Cameron McKenna Nabarro Olswang) and serves as the Legal Counsel for Alosenta. He is a specialist in VC, PE and M&A, with a particular focus on advising clients in the technology sector through all funding rounds to eventual exit.

Mr. Finnemore trained with a US law firm and has worked for international law firms throughout his career. He has substantial experience in PE/VC and is ranked in both the Chambers and Legal 500 guides for his expertise in this space.

Mr. Declan Murtagh is a digital and innovation consultant and co-founder of Brilliant Red Digital, specialising in helping startups and SMEs grow and scale through smart, data-driven strategies. With a background in marketing and innovation, Declan works on projects focused on customer discovery, market validation, and brand development—including building impactful websites and digital experiences.

He supports businesses through every stage of their journey, from launching new products to scaling through social media, SEO, paid campaigns, and content marketing.

Ms. Raimonda Karpavice is an accomplished finance and accounting professional and Account/Tax Counsel at Alosenta. She holds a First-Class BA in Business and Management from the University of Northampton and has experience across firms including Moore Kingston Smith, Shipleys LLP, and Konsus Ltd. Her expertise includes VAT and CIS reporting, reconciliations, P&L analysis, statutory accounts, and payroll. Known for strong analytical and leadership skills, she combines finance and operational experience to drive business efficiency and strategic planning.